Quick Answer
PROVECTUS BIOPHARMACEUTICALS, INC. reported Net Income of -$5.43 million for fiscal year 2025.
PROVECTUS BIOPHARMACEUTICALS, INC. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$5.43M | -14.8% |
| 2024 | -$4.73M | -52.6% |
| 2023 | -$3.10M | +12.7% |
| 2022 | -$3.55M | +35.8% |
| 2021 | -$5.54M | +17.0% |
| 2020 | -$6.68M | +3.5% |
| 2019 | -$6.92M | +15.1% |
| 2018 | -$8.15M | +39.7% |
| 2017 | -$13.52M | +44.7% |
| 2016 | -$24.43M | +0.3% |
| 2015 | -$24.50M | -139.2% |
| 2014 | -$10.24M | +63.0% |
| 2013 | -$27.70M | -120.4% |
| 2012 | -$12.57M | +35.3% |
| 2011 | -$19.43M | -4.8% |
| 2010 | -$18.55M | -50.6% |
| 2009 | -$12.32M | -20.0% |
| 2008 | -$10.27M | -2.6% |
| 2007 | -$10.01M | -12.8% |
| 2006 | -$8.87M | +24.6% |
| 2005 | -$11.76M | -170.8% |
| 2004 | -$4.34M | -37.7% |
| 2003 | -$3.16M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.31M | -29.3% | +27.7% |
| June 30, 2025 | -$1.81M | -114.3% | -59.1% |
| March 31, 2025 | -$1.14M | -126.2% | -12.4% |
| September 30, 2024 | -$1.01M | -30.7% | -19.8% |
| June 30, 2024 | -$846.8K | -1.4% | -68.0% |
| March 31, 2024 | -$504.0K | +39.1% | +35.0% |
| September 30, 2023 | -$775.8K | -8.8% | +7.1% |
| June 30, 2023 | -$835.1K | +22.5% | -0.9% |
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -14.8% in Net Income compared to the prior fiscal year.
- Over the 2003–2025 period, PROVECTUS BIOPHARMACEUTICALS, INC.’s net income has declined by 72.1% (from -$3.16 million to -$5.43 million).
- The most recent figure is from PROVECTUS BIOPHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: